Connect Biopharma: Attempting To Differentiate Rademikibart From Dupixent

CNTB is developing rademikibart, a drug with a similar mechanism of action to SNY/REGN's blockbuster Dupixent. The company is approaching a readout from two trials, Seabreeze STAT Asthma and Seabreeze STAT COPD, which have the potential to show a benefit of rademikibart for acute exacerbations. CNTB raised net proceeds of $18.6M in Q1'26 with a private placement, with cash of $46M at the end of that quarter.

Connect Biopharma Holdings Limited (CNTB) develops rademikibart, an antibody targeting interleukin-4 receptor alpha (IL-4Rα), for the treatment of asthma and chronic obstructive pulmonary disease (COPD). As an antibody targeting IL-4Rα, rademikibart shares its mechanism of action with blockbuster drug Dupixent (dupilumab).